Formulations of apremilast
US12427136B2 · kind B2 · utility
0Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2024 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Mar 21, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.